Biopharmaceutical company AstraZeneca plc (STO:AZN) (LON:AZN) (Nasdaq:AZN) reported on Friday positive high-level results from the global Phase III DUO-E trial showing that Imfinzi (durvalumab), when combined with platinum-based chemotherapy followed by either Imfinzi plus Lynparza (olaparib) or Imfinzi alone as maintenance therapy, demonstrated a statistically significant and clinically meaningful improvement in progression-free survival for patients with advanced or recurrent endometrial cancer.
This marks the first Phase III trial to demonstrate clinical benefit in this context by combining immunotherapy and PARP inhibition. The combination of Imfinzi and Lynparza as maintenance treatment showed greater clinical benefit.
AstraZeneca noted that although overall survival data were immature during the analysis, a favourable trend was observed for both treatment regimens.
Endometrial cancer is the sixth most common cancer in women globally, and there is a need for novel treatment options.
The safety and tolerability profiles of Imfinzi plus chemotherapy and Imfinzi in combination with Lynparza were consistent with prior trials and known profiles of the medicines.
GSK Launches COiMMUNITY Initiative to Help Achieve Higher Adult Vaccination Rates in the US
AstraZeneca's Lynparza receives US approval for BRCA-mutated prostate cancer
Nykode Therapeutics expands clinical collaboration with Roche for advanced cervical cancer trial
Caliway Biopharmaceuticals commences CBL-0204 Phase 2b study patient recruitment
Adiso Therapeutics completes Phase 1b multiple ascending dose clinical trial assessing ADS051
InDex Pharmaceuticals signs license agreement with Viatris Japan
Pfizer receives FDA approval for RSV vaccine in older adults
Brii Biosciences doses first subject in BRII-297 phase one clinical trial